Caprelsa (vandetanib) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	v::RET	Medullary Thyroid Cancer	Vandetanib